Johnson & Johnson (JNJ) announced updated results from the investigational Phase 1b RedirecTT-1 study evaluating the bispecific ...

Bayer AG and BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

Longboard Pharmaceuticals has commenced the international Phase III DEEp SEA Study of its investigational asset bexicaserin ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for paltusotine, the first once-daily, oral ...

This trial also includes an open-label portion for adults with type 1 diabetes up to 15 years since diagnosis. The open-label portion (n=40) is examining the efficacy, safety, and durability of ...

David Sallman, MD, discusses some of the innovative therapies and strategies being investigated in myelodysplastic syndromes studies.

The biotech sector was in focus last week, with regular pipeline and regulatory updates. Drug approvals were in the spotlight ...

Phase 1b study will evaluate the safety and tolerability of multiple ascending doses of RCT2100 in people with cystic fibrosis – ...

Sage Therapeutics announced Biogen's decision to terminate their collaboration on SAGE-324 following negative results from a ...

An international placebo-controlled study led by Cedars-Sinai suggests that a targeted drug therapy that was developed by ...

Shares of Celldex Therapeutics CLDX lost 12.1% on Wednesday due to unsatisfactory 52-week safety data from a mid-stage study ...